… Dabrafenib is orally bioavailable, doesn’t significantly accumulate after multiple dosing, and
… Additionally, while dabrafenib is very selective, we can’t exclude off-target effects that may …

Hyperactive signaling of the MAP kinase pathway resulting from the constitutively active B-Raf
V600E mutated enzyme has been observed in a number of human tumors, including …

Ensifentrine is a novel, potent, and selective dual inhibitor of phosphodiesterase (PDE)3
and PDE4 designed for delivery by inhalation that combines effects on airway inflammation, …

Two new series of potent and selective dual EGFR/ErbB-2 kinase inhibitors derived from
novel thienopyrimidine cores have been identified. Isomeric thienopyrimidine cores were …

… Watz H, Rickard K, Rheault T, Bengtsson T, Singh D. symptom improvement following
treatment with the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in patients with …

Activation of the Ras‐Raf‐MEK‐ERK pathway has been implicated in a large range of human
cancers. Growth factor receptor stimulation by extracellular ligands activates Ras, which …

… In addition to its expression in immune cells, including T cells, B cells, and dendritic cells,
CD38 is also expressed in multiple tissues, including bone, brain, intestine, kidney, liver, …

There is growing interest in asthma–chronic obstructive pulmonary disease (COPD) overlap
syndrome (ACOS) [1, 2]. Yet, there is no consensus on the best definition of ACOS [1, 2] and…

… For the generation of both diastereomers 60 and 61 the methyl acrylate approaches the
radical from the face opposite the bulky t-butyl group (62 and 63). The cyclization then takes …

Purpose Ensifentrine is an inhaled dual inhibitor of phosphodiesterase (PDE) 3 and 4 that
has shown bronchodilatory effects and symptom improvement in clinical studies in patients …